Advanced or metastatic solid tumors

This early-stage trial tests an experimental drug called ONO-4578, both on its own and together with another experimental drug, ONO-4538, in people with advanced or metastatic solid tumors. The study also includes separate groups for people with gastric cancer or colorectal cance…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This early-stage trial is testing an experimental drug called HM97662 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking two proteins, EZH1 and EZH2, which are thought to help tumors grow. The study aims t…

This early-stage trial is testing an experimental biologic called MK-1484, given alone or with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced or metastatic solid tumors. The main goal is to assess the safety and tolerability of the treatment and to find …

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This early-phase trial tests a new drug called KGX101, alone or with another drug (envafolimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the d…

This early-stage trial is testing whether a combination of two drugs, naporafenib and trametinib, can shrink or control advanced solid tumors that have a specific genetic change called RAS Q61X. About 86 people whose cancer has not responded to standard treatments will receive th…

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…